Routine treatment of insulin-dependent diabetic patients with ACE inhibitors to prevent renal failure: an economic evaluation

American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
Bryce A Kiberd, K K Jindal

Abstract

The objective of this study was to determine how effective angiotensin-converting enzymes (ACEs) must be in preventing diabetic nephropathy to warrant routine administration to insulin-dependent diabetic patients. A Markov model was used to compare three strategies designed to prevent the development of end-stage renal disease in insulin-dependent diabetic patients. Strategy I, screening for microalbuminuria and treatment of incipient nephropathy as currently recommended, was compared with strategy II, a protocol in which patients were routinely administered an ACE inhibitor 5 years after diagnosis of diabetes, and strategy III, in which patients at high risk for nephropathy were routinely treated and low-risk patients followed a protocol in which patients were treated with an ACE inhibitor if they developed hypertension and/or macroproteinuria. The model predicted that strategy II would produce as many quality-adjusted life-years as strategy I at nearly the same cost if routine drug therapy reduced the rate of development of microalbuminuria by 26% in all patients. Strategy III produced as many quality-adjusted life-years at less cost than strategy I if a high-risk cohort could be identified with a rate of developing microalbu...Continue Reading

Citations

Jan 20, 2004·Advances in Renal Replacement Therapy·Thomas H Hostetter
Nov 4, 2000·Expert Opinion on Investigational Drugs·G Ruiz-IrastorzaG R Hughes
Jul 15, 2005·Kidney International. Supplement·Rafael Burgos Calderón, Santos Depine
Mar 18, 2000·Archives of Physical Medicine and Rehabilitation·K J Kowalske, J C Agre
Oct 16, 2015·PloS One·Andrew J SuttonUNKNOWN eGFR-C study group
Oct 13, 2006·Journal of the American Society of Nephrology : JASN·Bryce Kiberd
Oct 28, 2005·Transplantation·Gerald B AppelEllen M Ginzler
Jan 15, 2004·PharmacoEconomics·Jonathan D RippinStephen C Bain
Sep 29, 2004·PharmacoEconomics·Frederick B DongMichael M Engelgau
Jan 23, 1999·Current Opinion in Nephrology and Hypertension·I A Hauser, R B Sterzel
Oct 22, 2005·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Mohsen S Eledrisi
Aug 6, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Thomas H Hostetter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.